Multiple and extensive R&D programs evaluate the validity of biomarkers and their suitability for diagnostic and companion diagnostic use.
Epigenetic insight and analysis show a significant advantage for the EpiSwitch™ read-out on many existing biomarkers, whose value at the level of genetic predisposition, RNA or protein levels of expression are insufficient for successful commercialisation.
